Literature DB >> 31422156

Multimerin-2 maintains vascular stability and permeability.

Rosanna Pellicani1, Evelina Poletto1, Eva Andreuzzi1, Alice Paulitti1, Roberto Doliana1, Dario Bizzotto2, Paola Braghetta2, Roberta Colladel1, Giulia Tarticchio1, Patrizia Sabatelli3, Francesco Bucciotti1, Giorgio Bressan2, Renato V Iozzo4, Alfonso Colombatti1, Paolo Bonaldo5, Maurizio Mongiat6.   

Abstract

Multimerin-2 is an extracellular matrix glycoprotein and member of the elastin microfibril interface-located (EMILIN) family of proteins. Multimerin-2 is deposited along blood vessels and we previously demonstrated that it regulates the VEGFA/VEGFR2 signaling axis and angiogenesis. However, its role in modulating vascular homeostasis remains largely unexplored. Here we identified Multimerin-2 as a key molecule required to maintain vascular stability. RNAi knockdown of Multimerin-2 in endothelial cells led to cell-cell junctional instability and increased permeability. Mechanistically cell-cell junction dismantlement occurred through the phosphorylation of VEGFR2 at Tyr951, activation of Src and phosphorylation of VE-cadherin. To provide an in vivo validation for these in vitro effects, we generated Multimerin-2-/- (Mmrn2-/-) mice. Although Mmrn2-/- mice developed normally and displayed no gross abnormalities, endothelial cells displayed cell junctional defects associated with increased levels of VEGFR2 phospho-Tyr949 (the murine counterpart of human Tyr951), impaired pericyte recruitment and increased vascular leakage. Of note, tumor associated vessels were defective in Mmrn2-/- mice, with increased number of small and often collapsed vessels, concurrent with a significant depletion of pericytic coverage. Consequently, the Mmrn2-/- vessels were less perfused and leakier, leading to increased tumor hypoxia. Chemotherapy efficacy was markedly impaired in Mmrn2-/- mice and this was associated with poor drug delivery to the tumor xenografts. Collectively, our findings demonstrate that Multimerin-2 is required for proper vessel homeostasis and stabilization, and unveil the possibility to utilize expression levels of this glycoprotein in predicting chemotherapy efficacy.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  angiogenesis; extracellular matrix; tumor growth; tumor microenvironment; vascular homeostasis

Year:  2019        PMID: 31422156     DOI: 10.1016/j.matbio.2019.08.002

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  10 in total

1.  Molecular Characterization of Limited Ulcerative Colitis Reveals Novel Biology and Predictors of Disease Extension.

Authors:  Carmen Argmann; Minami Tokuyama; Ryan C Ungaro; Ruiqi Huang; Ruixue Hou; Sakteesh Gurunathan; Roman Kosoy; Antonio Di'Narzo; Wenhui Wang; Bojan Losic; Haritz Irizar; Lauren Peters; Aleksandar Stojmirovic; Gabrielle Wei; Phillip H Comella; Mark Curran; Carrie Brodmerkel; Joshua R Friedman; Ke Hao; Eric E Schadt; Jun Zhu; Judy Cho; Noam Harpaz; Marla C Dubinsky; Bruce E Sands; Andrew Kasarskis; Saurabh Mehandru; Jean-Frederic Colombel; Mayte Suárez-Fariñas
Journal:  Gastroenterology       Date:  2021-09-02       Impact factor: 22.682

Review 2.  Proteomics and its applications in breast cancer.

Authors:  Anca-Narcisa Neagu; Danielle Whitham; Emma Buonanno; Avalon Jenkins; Teodora Alexa-Stratulat; Bogdan Ionel Tamba; Costel C Darie
Journal:  Am J Cancer Res       Date:  2021-09-15       Impact factor: 5.942

3.  Proteomic profiling of concurrently isolated primary microvascular endothelial cells, pericytes, and vascular smooth muscle cells from adult mouse heart.

Authors:  Zhiping Cao; Jessica Minnier; Lijuan Liu; Kristin L Lyon Scott; Ashok P Reddy; Phillip A Wilmarth; Larry L David; Anthony P Barnes; Marjorie R Grafe; Sanjiv Kaul; Nabil J Alkayed; Catherine M Davis
Journal:  Sci Rep       Date:  2022-05-25       Impact factor: 4.996

Review 4.  Role of Extracellular Matrix in Gastrointestinal Cancer-Associated Angiogenesis.

Authors:  Eva Andreuzzi; Alessandra Capuano; Evelina Poletto; Eliana Pivetta; Albina Fejza; Andrea Favero; Roberto Doliana; Renato Cannizzaro; Paola Spessotto; Maurizio Mongiat
Journal:  Int J Mol Sci       Date:  2020-05-23       Impact factor: 5.923

5.  Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma.

Authors:  Wenzhong Zheng; Shiqiang Zhang; Huan Guo; Xiaobao Chen; Zhangcheng Huang; Shaoqin Jiang; Mengqiang Li
Journal:  Cell Commun Signal       Date:  2021-03-24       Impact factor: 5.712

6.  Comment on: Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis by Jing Li et al.

Authors:  Scott Wilkinson; Adam G Sowalsky
Journal:  Transl Oncol       Date:  2022-01-22       Impact factor: 4.243

7.  CD93 Signaling via Rho Proteins Drives Cytoskeletal Remodeling in Spreading Endothelial Cells.

Authors:  Stefano Barbera; Luisa Raucci; Roberta Lugano; Gian Marco Tosi; Anna Dimberg; Annalisa Santucci; Federico Galvagni; Maurizio Orlandini
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 5.923

Review 8.  Multimerin-1 and cancer: a review.

Authors:  Mareike G Posner
Journal:  Biosci Rep       Date:  2022-02-25       Impact factor: 3.840

9.  Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy.

Authors:  Yi Sun; Wei Chen; Robert J Torphy; Sheng Yao; Gefeng Zhu; Ronggui Lin; Roberta Lugano; Emily N Miller; Yuki Fujiwara; Li Bian; Linghua Zheng; Sudarshan Anand; Fan Gao; Weizhou Zhang; Sarah E Ferrara; Andrew E Goodspeed; Anna Dimberg; Xiao-Jing Wang; Barish H Edil; Carlton C Barnett; Richard D Schulick; Lieping Chen; Yuwen Zhu
Journal:  Sci Transl Med       Date:  2021-07-28       Impact factor: 17.956

10.  The Binding of CD93 to Multimerin-2 Promotes Choroidal Neovascularization.

Authors:  Gian Marco Tosi; Giovanni Neri; Stefano Barbera; Lucia Mundo; Barbara Parolini; Stefano Lazzi; Roberta Lugano; Evelina Poletto; Lorenzo Leoncini; Grazia Pertile; Maurizio Mongiat; Anna Dimberg; Federico Galvagni; Maurizio Orlandini
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-07-01       Impact factor: 4.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.